Neuphoria Therapeutics Inc. (NEUP)
NASDAQ: NEUP · Real-Time Price · USD
3.360
+0.010 (0.30%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Neuphoria Therapeutics Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Operating Revenue | 1.17 | 15.65 | - | - | 0.18 |
Other Revenue | - | - | - | - | 3.99 |
| 1.17 | 15.65 | - | - | 4.17 | |
Revenue Growth | -92.50% | - | - | - | 499.60% |
Cost of Revenue | - | - | - | - | 11.02 |
Gross Profit | 1.17 | 15.65 | - | - | -6.85 |
Selling, General & Admin | 7.44 | 7.77 | 8.47 | 8.91 | 5.28 |
Research & Development | 2.74 | 8.71 | 9.32 | 12.65 | - |
Other Operating Expenses | - | - | - | - | -0 |
Operating Expenses | 10.18 | 16.48 | 17.8 | 21.56 | 5.27 |
Operating Income | -9.01 | -0.83 | -17.8 | -21.56 | -12.12 |
Interest Expense | - | - | - | - | -0.02 |
Interest & Investment Income | 0.67 | 0.17 | 0.22 | 0.32 | 0.01 |
Currency Exchange Gain (Loss) | -0.54 | -0.41 | -0.21 | 0.31 | 0.25 |
Other Non Operating Income (Expenses) | - | - | - | -0.59 | -2.59 |
EBT Excluding Unusual Items | -8.88 | -1.08 | -17.79 | -21.52 | -14.48 |
Merger & Restructuring Charges | -1.28 | - | - | - | - |
Impairment of Goodwill | -5.36 | - | - | - | - |
Gain (Loss) on Sale of Investments | 1.93 | 0.24 | 2.21 | - | - |
Gain (Loss) on Sale of Assets | - | - | - | - | -0 |
Other Unusual Items | - | - | - | - | -0.65 |
Pretax Income | -13.59 | -0.84 | -15.58 | -21.52 | -15.12 |
Income Tax Expense | -0.14 | -0.47 | -0.09 | -0.14 | -0.13 |
Earnings From Continuing Operations | -13.45 | -0.37 | -15.49 | -21.38 | -14.99 |
Net Income | -13.45 | -0.37 | -15.49 | -21.38 | -14.99 |
Net Income to Common | -13.45 | -0.37 | -15.49 | -21.38 | -14.99 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 4 | 2 | 1 | 1,469 | 1,353 |
Shares Outstanding (Diluted) | 4 | 2 | 1 | 1,469 | 1,353 |
Shares Change | 170.85% | 95.01% | -99.94% | 8.53% | 73.52% |
EPS (Basic) | -3.06 | -0.23 | -18.62 | -0.01 | -0.01 |
EPS (Diluted) | -3.06 | -0.23 | -18.62 | -0.01 | -0.01 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -12.35 | 0.08 | -14.68 | -14.64 | -14.99 |
Free Cash Flow Per Share | -2.81 | 0.05 | -17.64 | -0.01 | -0.01 |
Gross Margin | 100.00% | 100.00% | - | - | -164.21% |
Operating Margin | -767.32% | -5.30% | - | - | -290.62% |
Profit Margin | -1145.66% | -2.36% | - | - | -359.34% |
Free Cash Flow Margin | -1052.07% | 0.49% | - | - | -359.30% |
EBITDA | -8.35 | -0.17 | -17.13 | -20.9 | -11.49 |
EBITDA Margin | - | -1.06% | - | - | -275.36% |
D&A For EBITDA | 0.66 | 0.66 | 0.66 | 0.66 | 0.64 |
EBIT | -9.01 | -0.83 | -17.8 | -21.56 | -12.12 |
EBIT Margin | - | -5.30% | - | - | -290.62% |
Revenue as Reported | 1.17 | 15.65 | - | - | - |